A new study published in eBioMedicine suggests that long COVID-related neuropsychiatric symptoms—such as brain fog and memory loss—may stem from measurable damage to the brain’s dopamine system. Researchers from the University of Toronto and the Brain Health Imaging Centre found that patients with long COVID exhibit a 16% to 20% reduction in VMAT2, a critical marker for dopamine neuron integrity, compared to healthy individuals.
Evidence of Dopaminergic System Injury
The research team utilized positron emission tomography (PET) imaging to examine the brains of 24 adults suffering from long COVID alongside 24 healthy control subjects. The study identified significantly lower levels of vesicular monoamine transporter 2 (VMAT2) in the striatum, the area of the brain responsible for motivation, reward processing, motor control, and cognition.
According to Jeffrey Meyer, MD, PhD, a senior scientist at the Brain Health Imaging Centre and senior study author, the observed loss of dopamine-releasing neurons explains common patient complaints. “This kind of injury is well known to produce symptoms like lack of motivation and motor slowing,” Dr. Meyer stated in a news release from the Centre for Addiction and Mental Health.
Did you know? The study found that the dorsal putamen—a region heavily involved in movement—showed the largest reduction in VMAT2 levels, while the ventral striatum, linked to reward and motivation, showed the smallest decrease.
Shifting Toward Mechanistic Treatments
The findings offer a potential roadmap for future clinical interventions. By identifying a specific biological pathway, the research moves the conversation around long COVID from symptom observation to “mechanistic stratification,” according to an accompanying commentary by Eric Guedj, MD, PhD, of Aix Marseille University, and Danielle Beckman, PhD, PharmD, of Helmholtz Munich.
Dr. Meyer suggests that these results open the door to repurposing existing medications. Because the study identifies a deficit in dopamine-releasing neurons, drugs that augment dopamine function or inhibit dopamine metabolism could eventually be tested as therapies for patients experiencing persistent neuropsychiatric effects.
Limitations and Future Directions
While the study provides a biological framework, researchers emphasize that the results demonstrate an association rather than direct causation. The study was limited by a small sample size and a focus specifically on patients already experiencing significant neuropsychiatric symptoms.
Dr. Guedj and Dr. Beckman noted that the observed changes in the dopamine system are not necessarily permanent. Further longitudinal research is required to determine the clinical significance of these findings and whether the dopamine deficiency can be reversed over time.
Pro Tip: Keep track of emerging clinical trials.
Frequently Asked Questions
What is VMAT2 and why does it matter in long COVID?
VMAT2 is a protein that acts as a marker for the integrity of dopamine neurons. Lower levels suggest a loss of these neurons, which are essential for motivation, motor control, and cognitive function.
Can these brain changes be reversed?
The current study does not confirm whether the damage is permanent. Experts note that more longitudinal studies are needed to understand the long-term clinical trajectory of these dopaminergic changes.
What are the primary symptoms associated with this dopamine deficit?
Patients in the study reported symptoms including brain fog, memory problems, difficulty concentrating, lack of motivation, and motor slowing.
Are you interested in learning more about the latest developments in post-viral research? Subscribe to our newsletter for updates on emerging science and clinical trial breakthroughs.
Worth a look